|
Sangamo BioSciences specializes in DNA
binding proteins for the therapeutic regulation and modification of
disease-related genes.
Technology platform: Is based on the engineering of a
class of proteins known as zinc finger DNA-binding proteins (ZFPs). ZEPs are used to make ZFP transcription factors, or ZFP
TFs ZFP
TFs: These are proteins that bind to DNA and are able to turn genes on or off.
Its ZFPs are also engineered to create zinc finger nucleases, or ZFNs, which
are used to cut genomic DNA at a pre-selected sequence location, enabling ZFN-mediated
disruption of genes that facilitate or are responsible for disease pathology;
correction of genes that contain disease-causing mutations; or the targeted
addition of a selected DNA sequence.
The company’s product development programs
using ZFPS, ZFP TFs, and ZFNs include the phase 2 clinical trial in diabetic
neuropathy; phase 1 clinical trial in peripheral artery disease; and various preclinical-stage
programs and research-stage programs in human immunodeficiency virus infection
and acquired immune deficiency syndrome, oncology, ischemic heart disease,
congestive heart failure neuropathic pain, nerve regeneration, age-related
macular degeneration, and Parkinson’s disease.
Sangamo BioSciences has
agreements with LifeScan, Inc.; Amgen; Novartis; Novo Nordisk A/S; and Dow
AgroSciences LLC.
The company was founded in 1995 and is based in Tichmond, Virginia. NEWS
2008
Sangamo BioSciences Reports Second Quarter 2008 Financial Results Jul 23, 2008 Sangamo BioSciences Announces Second Quarter Conference Call and Webcast Jul 16, 2008
Sangamo
BioSciences and Sigma-Aldrich Announce Research and License Agreement
With Roche for the Use of ZFN Technology for Generation of Transgenic
Animals
Jul 9, 2008 Sangamo
BioSciences Announces Nature Biotechnology Study Demonstrating the Use
of Zinc Finger Nucleases to Generate HIV Resistant T Cells Jun 30, 2008 Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants Jun 18, 2008 Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting Jun 8, 2008 Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
Jun 6, 2008 Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration Jun 5, 2008 Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference May 29, 2008 FORWARD-LOOKING STATEMENT: Prohost is independent publication
providing information on biotech companies. Prohost does not accept
compensation from companies that are featured or profiled.It is strongly
recommended that any purchase or sale decisions to any of the featured
companies be discussed with a financial advisor or broker prior to completing
any such purchase or sale decision. All statements or expressions are the
opinion of Prohost and are not meant to be a solicitation or recommendation to
buy, sell, or hold securities. Investing in embryonic companies, micro-capand
growth securities is highly speculative and carries a high degree of risk. It
is possible that an investor can lose all of his/her investment in this type of
companies that are profiled. The information that Prohost relies on is either
through the profiled company, news services, research reports, interviews, or
other outside sources that Prohost believes are reliable. Prohost makes no
representations, warranties or guarantees as to the accuracy or completeness of
the disclosure of the profiled companies and accepts no responsibilities for
inaccuracies or misleading content in any material supplied by those
clients.There can be no assurance that future events relating to the profiled
company will occur as anticipated.The information contained herein is provided
as an information service only.Past performance of featured companies does not
guarantee the future success of any currently featured or profiled company. We
encourage our readers to invest carefully and read the investor information
provided by the Securities and Exchange Commission ("SEC")and/or the
National Association of Securities Dealers ("NASD")We strongly
recommend that you read theSEC advisory to investors concerning Internet Stock
Fraud, which can be found at : http://www.sec.gov/consumer/cyberfr.htm.
|
